Voyager Therapeutics, Inc. - 8-K Filing
Voyager Therapeutics reported first-quarter 2026 financial results, including $2.6 million in collaboration revenue, $24.6 million in R&D expenses, and a net loss of $27.9 million. The company ended Q1 with $171.7 million in cash, providing a runway into 2028. It also announced clinical progress, including completion of IND-enabling GLP toxicology for VY1706, with first-in-human dosing expected in H2 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits(d) ExhibitsThe following exhibit relating to Item 2)
Tickers: $VYGR